KHAVINSON PEPTIDES® TECHNOLOGY AND NANOPEP®

In 1901, Emil Fischer suggested the peptide theory of protein structure and synthesized the first dipeptide. The Nobel laureate launched the exploration trend that the gerontologist Vladimir Khavinson followed later by extracting physiologically active peptides, which are used in peptide bioregulator products marketed in the Western market these days.

Peptide bioregulators have aroused great appeal over the past couple of decades, as they contribute to healthy and active longevity. The reverse aging is one of the reasons for the active online search for information about “KHAVINSON PEPTIDES®.”

People across Europe and the United States want to know more about recent research and new products on this subject. However, the lack of information prevents understanding the nature and effect of KHAVINSON PEPTIDES®, the way peptide bioregulators differ from each other, and which ones comply with Western standards and are safe to take.

We’ll explain how KHAVINSON PEPTIDES® technology is used when NANOPEP® products are manufactured and how it is introduced on European and US markets.

WHAT ARE KHAVINSON PEPTIDES®?

KHAVINSON PEPTIDES® are short-chain amino acids that are used in bioregulating peptide therapy. Initially, Professor Vladimir Khavinson extracted and synthesized physiologically active peptides. After years of studies, they were officially permitted to be used for medical purposes in Russia.

Further research in gerontology and molecular biology has proven the effectiveness of short peptides in the processes related to cellular communication and modulating gene expression. They improve antioxidant protection, mitochondrial function, and contribute to tissue renewal. All of these and other actions increase the lifespan. In such a way, short peptides regulate natural processes instead of stimulating or suppressing them.

Nowadays, this technology is used to develop new products by various companies from all over the world. Thus, when they say “KHAVINSON PEPTIDES,” it means that the original scientific approach is used to produce food supplements. It is not about a particular commercial brand. KHAVINSON PEPTIDES can be used as a generic term.

FROM SCIENTIFIC ORIGIN TO WESTERN MARKET REQUIREMENTS

Nowadays, the attention of the Western consumer health market is focused on further aspirations related to short peptide products, which have not been widely explored yet, including:

• comprehensive classification indicating that products are intended for humans to consume;
• GMP-certified manufacturing facilities;
• open access to understandable information about quality control;
• ensuring that operational practices comply with EU and US standards;
• uninjectable formats designed for easy and safe use.

Satisfying the above expectations involves a lot of changes. It is not enough just to restructure the original formulations, adjusting them to production excellence.

NANOPEP®: A WESTERN IMPLEMENTATION OF KHAVINSON PEPTIDES® TECHNOLOGY

NANOPEP® products are developed as an advanced adoption of KHAVINSON PEPTIDES® technology. They are aimed at European and American markets, being different because:

• they are intended for human consumption only;
• they can be taken by mouth or sublingually;
• manufacturing facilities are located in Europe (Italy and Portugal) and are GMP-certified;
• finished goods are stored in warehouses in Europe and the United States until they are distributed.

Thus, NANOPEP makes every effort to employ a new scientific approach focused on the adaptation of the original concept to Western compliance requirements and industry regulations.

SCIENTIFIC VALIDATION BEFORE MANUFACTURING

To follow the original practices of KHAVINSON PEPTIDES®, NANOPEP applies testing of a NANOPEP® product peptide formulation before the launch of manufacturing. The process involves two stages:

• scientific validation in the original research environment tailored to study peptide bioregulators;
• manufacturing in facilities that comply with European standards.

As a part of scientific research (within the St. Petersburg Institute of Bioregulation and Gerontology and linked research laboratories), this test is intended to prove the biological activity of the product and its stability at the cellular level. If these two key performance metrics are confirmed, NANOPEP® is delivered to European GMP-certified facilities.

RESEARCH USE ONLY PEPTIDES VS. NANOPEP®

Online, there are lots of peptide products for research use, which means they are designed to be used in controlled laboratory environments. They cannot be offered for mass consumption, and they do not fall within the scope of dietary supplement regulations.

NANOPEP® products are “fit for human consumption,” which means they meet safety requirements by being produced and handled accordingly. This label is dramatically crucial for consumers who want to benefit from safe and efficient peptide bioregulators and look for quality products on the Western market.

FINAL THOUGHTS

KHAVINSON PEPTIDES® kickstarted scientific studies and clinical trials of peptide biological activities, being at the forefront of the growing trend. On the basis of the technology, NANOPEP develops and produces modern products complying with the standards in Europe and the United States.

NANOPEP makes people confident about peptide bioregulators by bringing together the original research practices (scientific validation) and security assurances by meeting the European system of mandatory minimum standards for production processes (GMP) and strict Western regulations.